AR059672A1 - Metodo para reducir los efectos toxicos de la nicotina sobre el feto en mujeres embarazadas - Google Patents

Metodo para reducir los efectos toxicos de la nicotina sobre el feto en mujeres embarazadas

Info

Publication number
AR059672A1
AR059672A1 ARP070100813A ARP070100813A AR059672A1 AR 059672 A1 AR059672 A1 AR 059672A1 AR P070100813 A ARP070100813 A AR P070100813A AR P070100813 A ARP070100813 A AR P070100813A AR 059672 A1 AR059672 A1 AR 059672A1
Authority
AR
Argentina
Prior art keywords
nicotine
fetus
reducing
toxic effects
pregnant women
Prior art date
Application number
ARP070100813A
Other languages
English (en)
Inventor
Soflane Ennifar
James Terril
Scott Winston
Steve Fuller
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Publication of AR059672A1 publication Critical patent/AR059672A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para reducir los efectos adversos de la nicotina. En esta solicitud se describe el uso de conjugados transportadores de nicotina para disminuir los efectos toxicos de la nicotina en un feto.
ARP070100813A 2006-02-27 2007-02-27 Metodo para reducir los efectos toxicos de la nicotina sobre el feto en mujeres embarazadas AR059672A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77666706P 2006-02-27 2006-02-27

Publications (1)

Publication Number Publication Date
AR059672A1 true AR059672A1 (es) 2008-04-23

Family

ID=38212270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100813A AR059672A1 (es) 2006-02-27 2007-02-27 Metodo para reducir los efectos toxicos de la nicotina sobre el feto en mujeres embarazadas

Country Status (3)

Country Link
US (1) US7547712B2 (es)
AR (1) AR059672A1 (es)
WO (1) WO2007100755A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982729A1 (en) * 2007-04-20 2008-10-22 Cytos Biotechnology AG Vaccination Regimen for B-Cell Vaccines
US9333270B2 (en) * 2013-03-15 2016-05-10 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
CN106133139A (zh) 2013-12-20 2016-11-16 斯克利普斯研究院 有关诱导感觉神经元的方法和组合物
US20170107275A1 (en) 2014-05-19 2017-04-20 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
MX2020001725A (es) 2017-08-15 2020-08-20 BliNK Biomedical Anticuerpos de fijacion a nicotina novedosos.
EP3801594A1 (en) 2018-06-06 2021-04-14 Antidote Therapeutics, Inc. Methods for improving circulation and treating cardiovascular disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction

Also Published As

Publication number Publication date
US20070212364A1 (en) 2007-09-13
WO2007100755A1 (en) 2007-09-07
US7547712B2 (en) 2009-06-16

Similar Documents

Publication Publication Date Title
GT200500269A (es) Procedimiento
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
ECSP077129A (es)
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
AR059672A1 (es) Metodo para reducir los efectos toxicos de la nicotina sobre el feto en mujeres embarazadas
AR066131A1 (es) Nuevos (met) acrilatos de uretano y su uso en composiciones de recubrimiento curables
GT200900292A (es) "inhibidores de cinasa p70 s6"
UY33124A (es) Agentes y epítopos enlazados a wise
CO6311002A2 (es) Agentes fijadores y epitopos wise
DK1740616T3 (da) Anti-TFR-antistof
PA8796201A1 (es) Agentes anti-infecciosos y su uso
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
HN2006037713A (es) Compuestos utiles en terapia
BRPI0914319A2 (pt) anticorpos estáveis e solúveis que inibem tnfalfa
HN2007006799A (es) Analogos de biaril piperazinil-piridina sustituidos
GT200600369A (es) Proceso
EA200802319A1 (ru) Способ и устройство для ремонта элементов конструкции
CL2008000510A1 (es) Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
ATE415385T1 (de) Hexafluorisopropanolsubstituierte etherderivate
PA8778601A1 (es) Inhibidores de la unión entre hdm2 y el proteasoma
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
UY31563A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
PA8624601A1 (es) Macrolidos y metodos para producir los mismos
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
GT200500385A (es) Aminoalcoholes triciclicos, procedimientos para su preparacion y su uso como inhibidores de inflamacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure